AA
DNLI icon

ALPS Advisors’s Denali Therapeutics DNLI Stock Holding History

ALPS Advisors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.12M Buy
160,378
+31,273
+24% +$643K 0.02% 325
2026
Q1 		$2.48M Buy
129,105
+8,387
+7% +$167K 0.01% 365
2025
Q4 		$1.99M Buy
120,718
+50,488
+72% +$852K 0.01% 394
2025
Q3 		$1.02M Sell
70,230
-8,126
-10% -$117K 0.01% 508
2025
Q2 		$1.1M Sell
78,356
-33,019
-30% -$465K 0.01% 484
2025
Q1 		$1.51M Sell
111,375
-5,002
-4% -$95.8K 0.01% 388
2024
Q4 		$2.37M Buy
116,377
+10,130
+10% +$259K 0.02% 320
2024
Q3 		$3.09M Sell
106,247
-4,992
-4% -$124K 0.02% 291
2024
Q2 		$2.58M Buy
111,239
+13,090
+13% +$251K 0.02% 305
2024
Q1 		$2.01M Buy
98,149
+187
+0.2% +$3.51K 0.01% 348
2023
Q4 		$2.1M Sell
97,962
-3,438
-3% -$68.1K 0.02% 324
2023
Q3 		$2.09M Buy
101,400
+780
+0.8% +$19.8K 0.02% 314
2023
Q2 		$2.97M Buy
100,620
+10,575
+12% +$297K 0.03% 250
2023
Q1 		$2.07M Sell
90,045
-1,984
-2% -$54.6K 0.02% 283
2022
Q4 		$2.56M Buy
92,029
+24,706
+37% +$735K 0.02% 256
2022
Q3 		$2.07M Sell
67,323
-5,617
-8% -$183K 0.02% 304
2022
Q2 		$2.15M Buy
+72,940
New +$1.91M 0.02% 308

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

ALPS Advisors's DNLI Position: Q2 2026 in Review

ALPS Advisors increased its Denali Therapeutics (DNLI) stake by 24% in Q2 2026, buying an estimated $643K and bringing the position to 160,378 shares worth $4.12M. The position accounts for 0.02% of the portfolio, ranked #325.

ALPS Advisors first reported a position in DNLI in Q2 2022 and has held it in 17 quarters since. 112 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • ALPS Advisors held 160,378 shares of Denali Therapeutics worth $4.12M as of Q2 2026.
  • ALPS Advisors bought 31,273 Denali Therapeutics shares in Q2 2026, an estimated $643K.
  • Denali Therapeutics made up 0.02% of ALPS Advisors's portfolio in Q2 2026, its #325 holding.
  • ALPS Advisors first reported a position in Denali Therapeutics in Q2 2022 and has held it in 17 quarters since.
  • 112 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.